GTRI flags proposed US generic-drug tariffs as major risk for Indian pharma exporters
A proposed US tariff path—0% for two years from August 1, then 100% for a year and 200% thereafter—could pressure Indian drugmakers. India sent $9.7 billion, or 37.7%, of its $25.8 billion pharmaceutical exports to the US in 2025, according to GTRI.
What happened
Indian pharmaceutical industry · GTRI said proposed US tariffs of up to 200% on generic drugs could significantly hit Indian pharma exports, particularly
Key facts
- 0% US tariff on generic drugs for two years from August 1
- 100% tariff for one year after the initial two-year period
- 200% tariff thereafter
- India exported $25.8 billion in pharmaceuticals in 2025
- $9.7 billion, or 37.7%, of Indian pharma exports went to the US
- Indian companies supply 47% of US generic prescriptions
- India's estimated share of US generic-import value is 30%
- US imported $213 billion of pharmaceutical products in 2025
Why this matters
This tariff path could accelerate acquisitions, manufacturing partnerships, and contract-development deals that give Indian pharma companies US production capacity or provide buyers with alternative generic supply.
What to watch
- Publication of formal tariff authority, product scope, country-of-origin rules and the exact August 1 effective date.
- Whether finished-dose generics, active pharmaceutical ingredients, biosimilars and essential-medicine lists receive different treatment.
- US FDA shortage-list additions or warnings about limited domestic production capacity.
- Announcements by Indian drugmakers of US acquisitions, new plants, local partnerships or US inventory builds.
- Comments from major US wholesalers, pharmacy chains, hospital associations, insurers and generic-drug trade groups on expected patient-cost impacts.
- India-US trade negotiations and any tariff exemptions linked to investment or supply-security commitments.
- Indian generic manufacturers should map US revenue and SKU exposure, separating commoditized products from medicines with limited alternative supply.
- Exporters should evaluate US manufacturing, fill-finish, packaging, contract-manufacturing and inventory-positioning options before the tariff implementation window.
- US pharmacy retailers, wholesalers and health systems should identify Indian-source concentration by molecule and qualify alternative suppliers early.
- Retail pharmacy operators should prepare for higher generic acquisition costs, shortage-related dispensing substitutions and payer reimbursement lag.
- Indian industry groups and US healthcare purchasers will likely lobby for exclusions tied to essential medicines, shortage risk and domestic-capacity gaps.